Lytix Biopharma is a clinical-stage patient-focused biopharmaceutical company developing novel  immunotherapies to fight cancer. Lytix’s immunotherapy approach is based on nature’s own defense mechanisms. The membranes of cancer cells are destroyed. Our unique technology is a new class of cancer immunotherapy that activates the patient`s own immune system.

Lytix conducts its research and development of drug candidates both in its own R&D department and through partnerships with other organizations. We aspire to continuously strengthen the position of our drug candidates by establishing long-term strategic and value creating collaborations within the pharma and biotech industry as well as with academic institutions.

Lytix’s strategy is to develop drug candidates through clinical phase II, but the company may consider out-licensing or co-development partnerships if appropriate at an earlier stage.

We are committed to alliances, partnerships, and collaborations and will opportunistically evaluate assets that have the potential to expand our pipeline or technological base.

To contact us regarding possible collaboration and partnership, please send an e-mail to